First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

NCT07699952 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)
EGFR Activating Mutation
HER2

Interventions

DRUG: Almonertinib
DRUG: Trastuzumab Rezetecan

Sponsor

Yongsheng Wang